Kiora Pharmaceuticals (NASDAQ:KPRX)
- Dollar Amount of Shares Purchased
- $64,388.79
- Number of Insider Purchases in the Last 180 Days
- 6
- Volume of Shares Purchased
- 14,041
- Who Bought Shares
- Aron Shapiro (Director), Brian M Strem (CEO), Eric Joseph Daniels (Insider), Erin Parsons (Director), Lisa Walters-Hoffert (Director) and Melissa Tosca (EVP)
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.
Read More
